FGF4 and diabetic kidney disease: In these human models, rFGF4 effectively reverses morphological abnormalities, reduces oxidative stress, and prevents podocyte loss under high glucose conditions, thus providing robust evidence that FGF4 is a promising therapeutic target for DKD.